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Background and Goal of Study: Aprotinin (AP) is a proteinase inhibitor drug. 
Initially introduced into clinical practice for the treatment of hyperfibrinolitic 
conditions, it was later used to reduce perioperative blood loss and transfusion 
needs. Preliminary data from the BART study suggesting an increased mortality in 
APtreated patients, led to its marketing withdrawal in 2008. In 2012, the European 
Medicine Agency revisited the totality of AP data and concluded that AP still has   
a place in preventing blood loss in patients undergoing isolated coronary artery 
bypass graft (iCABG) who are at high risk of major blood loss. As a condition to the 
reinstatement of AP’s marketing authorisation, the Nordic Aprotinin Patient Registry 
(NAPaR, EUPAS11384) has been established, with AP distribution restricted to 
centres that perform cardiac surgery on cardio-pulmonary bypass and commit to 
participate in the Registry. NAPaR main objectives are to record information on the 
use of AP in Europe and to measure incidence of selected adverse events (death, 
thromboembolic event, renal dysfunction, anaphylaxy) and effectiveness of risk 
minimisation measures (anticoagulation monitoring, AP’s test dose). Preliminary 
data on mortality rates are described. 
Materials and Methods: Following AP relaunching, all patients exposed to AP 
must be entered in the NAPaR. Data are to be collected for at least 3 years or 
after inclusion of 12000 patients and upon Pharmacovigilance Risk Assessment 
Committee decision. Every 6 months, a Data and Safety Monitoring Committee 
(DSMC) reviews the data and advices Nordic whether or not it is recommended to 
continue the NAPaR. 
Results and Discussion: The first patient was entered in the NAPaR in Feb-2016. 
Up to Jul-2018, 1419 adult patients have been treated with AP: 1175 (82.8%) from 
UK, 148 (10.4%) from Germany, 91 (6.4%) from Sweden, 3 (0.2%) from Austria 
and 2 (0.1%) from Finland. Only 3/314 patients treated on-label died, leading to an 
in-hospital mortality rate of 0.96%. 
Conclusions: No safety signals compromising the completion of the study have 
been identified by the DSMC. The overall mortality rate is in line (or even better) 
with studies without AP.1,2 
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Background: Factor VII Padua is a type 2 variant congenital factor VII deficiency. 
We discuss the management conundrum in reduction of blood loss versus achieving 
anticoagulation during endovascular surgery in such a patient. 
Case Report: We report a case of a 59 year old man with Factor VII Padua, planned 
for endovascular aortic aneurysm repair for a penetrating aortic ulcer. Rotational 
thromboelastometry (ROTEM) was used to guide the management of bleeding risk 
whilst maintaining anticoagulation during graft deployment. His baseline EXTEM 
showed an isolated prolonged clotting time (CT) as expected of his condition. 1.5mg 
of recombinant factor VIIa (Novoseven) was given 4 hours prior to surgery. EXTEM 
performed 42 minutes post NovoSeven administration showed a normalization    
of CT without further top-up doses, allowing surgical incision to proceed. Serial 
EXTEMs showed that further doses of Novoseven were not required. Heparin  
was omitted due to its unpredictable profile in factor VII deficiency.The patient was 
discharged 3 days after an uneventful procedure with minimal blood loss. 
Discussion: Prothrombin time(PT)/International Normalized Ratio is conventionally 
used to guide NovoSeven dosing, but it has a long laboratory turnover. Conversely, 
ROTEM’s fast result turnover time allows for rapid decision-making and guidance of 
further doses of NovoSeven, and is especially useful if there is significant bleeding. 
 
In particular, the EXTEM uses tissue factor as an activator, providing information 
on the extrinsic pathway factor activity similar to the PT. Also, ROTEM depicts the 
whole clotting process and can be used to rule out other causes of bleeding and 
identify hypercoagulability1. It allowed us to tread a fine line between maintaining  
a normal coagulation profile in view of arterial cannulation and a slightly anti- 
coagulated state during the stent deployment. We do not want to tip the patient into 
a prothrombotic state by over-dosing NovoSeven. 
References: 
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Learning points: ROTEM allows for quick monitoring of the patient’s coagulation 
status to reduce bleeding during femoral access, while achieving an anticoagulated 
state desirable for graft deployment. Further studies can evaluate its effectiveness 
in assessing post-operative hypercoagulopathic complications. 
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Background and goal of study: Aortic dissecton type 1 is associated with high 
perioperative complications and a significant operative mortality. Frozen Elephant 
Trunk (FET) technique is one of the latest to be introduced to treat extensive     
and complex lesions of the thoracic aorta, including the descendent portion. FET 
(Thoraflex™ hybrid graft) allows to treat aortic arch and descending thoracic lesions 
in one-time surgery with promising results. The goal of this study is to compare 
complications and transfusion rates in pacients with Thoraflex™ hybrid graft in our 
hospital and those from national and international registries. 
Materials and Methods: We retrospectively studied 10 patients who underwent 
total aortic arch replacement with Thoraflex™ hybrid graft between 2016 and 2018 
in Puerta de Hierro Hospital. We considered intraoperative extracorporeal data, 
transfusion rates, perioperative complications and one month mortality. Statistical 
analysis was performed using SPSS. 
Results and Discussion: There were no differences in intraoperative data and 
transfusion rates. Respiratory complications were significantly higher in our group. 
30% of the patients developed tracheobronchial compression by the aortic false 
lumen, wich increase significantly ICU stay. Paraplegia appeared in only one patient 
(10%) as a late complication (45 days before surgery) by an embolic event. 
Conclusions: Tracheobronchial compression  by  the  aortic  false  lumen  was  
an important complication in postoperative total aortic arch replacement with 
Thoraflex™ hybrid graft. 
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Background: Operating room fires are a rare but potentially catastrophic 
occurrence1.We report a case of a chest cavity fire associated with an air leak due 
to a ruptured bulla. 
Case Report: A 60-year-old man presented for emergency repair of a type A aortic 
dissection. Past medical history was significant for chronic obstructive pulmonary 
disease and coronary artery bypass grafting one year prior. After induction, general 
anesthesia was maintained with inhaled sevoflurane (MAC 1) and intravenous 
propofol infusion (150 mg/hr). Surgery proceeded to sternotomy. At this point his 
right lung was noted to be adherent to the overlying sternum with prominent bullae. 
Despite careful dissection one of these bullae was punctured during sternotomy 
causing a significant air leak. In order to compensate for this the flows on the 
anesthetic machine were increased to 10 liters per minute and the proportion of 
inspired oxygen increased to 100%. Such was the extent of the leak that there 
were comments by the surgical team about the smell of sevoflurane. Shortly after 
this a dry pack in the presence of diathermy caught fire. This was immediately 
